The Centers for Disease Control and Prevention’s advisory committee did not vote Wednesday on whether to extend the country’s pause against Johnson & Johnson’s COVID-19 vaccine, after experts from the group say there is still not enough data to make final recommendations. in light of the serious, rare clotting events potentially associated with the shots.
While the CDC’s current pause on Johnson and Johnson’s vaccine is not binding, a warning issued by federal health officials on Tuesday urged vaccinations to be suspended only until the commission votes on “updated recommendations”
The CDC has not yet decided on a date for the resumption of the panel’s discussion on the topic.
“Your opinion today was extremely helpful in helping to inform our work next week,” said Dr. Amanda Cohn, the agency’s appointed federal adviser to the advisory committee.
“To be very honest, I do not want to vote on this issue today,” Dr Beth Bell, a member of the committee and a former CDC infectious disease officer, told the committee.
“I just don’t think that was enough information to make an evidence-based decision. We won’t have all the information, but I think there are some things we can gather relatively quickly, and they all have to do with the benefit balance. of risk, “added Dr. Bell.
A working group within the group said it had discussed a number of options this week, including recommending using the vaccine only for certain groups of people or abandoning it altogether, but concluded that more data were needed on these and other possible cases. can be reported.
White House officials said the pause in vaccinations against Johnson and Johnson was likely to affect the national vaccination campaign in the “very short term,” but insisted that supplies from Pfizer and Moderna were sufficient to meet their targets.
Ongoing trials of the single vaccine have been discontinued after the initial break. The spread of the vaccine abroad was also halted following the recommendation, as were key programs launched by U.S. state and local authorities to use the shots to vaccinate more hard-to-reach communities.
“We are in a situation where not making a decision is tantamount to making a decision. Any extension of the break will inevitably lead to the fact that the most vulnerable people in the United States, who were the main candidates for the Johnson & Johnson vaccine, will remain vulnerable, “Maine CDC Director Dr. Nirav Shah, president of the Association of State and Territorial Health Professionals, told the commission.
Representatives of Johnson and Johnson, the Food and Drug Administration, and CDC staff made presentations to the committee, outlining several new details of the cases known so far.